Becton, Dickinson and Company (BDX)

US — Healthcare Sector
Peers: EW  CAH  ARGX  ALC  RMD  A  VEEV  IDXX  IQV  HLN 

Automate Your Wheel Strategy on BDX

With Tiblio's Option Bot, you can configure your own wheel strategy including BDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BDX
  • Rev/Share 76.1971
  • Book/Share 88.5832
  • PB 2.3311
  • Debt/Equity 0.7555
  • CurrentRatio 1.1133
  • ROIC 0.0473

 

  • MktCap 58938935738.0
  • FreeCF/Share 9.3157
  • PFCF 22.0745
  • PE 35.2714
  • Debt/Assets 0.3467
  • DivYield 0.0202
  • ROE 0.0663

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 5
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed BDX Citigroup -- Buy -- $233 Feb. 3, 2026
Initiation BDX RBC Capital Mkts -- Sector Perform -- $211 Sept. 25, 2025
Downgrade BDX Citigroup Buy Neutral -- $185 May 22, 2025
Downgrade BDX Raymond James Outperform Market Perform -- -- May 2, 2025
Downgrade BDX Goldman Buy Neutral -- $192 May 2, 2025
Downgrade BDX Piper Sandler Overweight Neutral -- $185 May 2, 2025
Downgrade BDX William Blair Outperform Market Perform -- -- May 1, 2025
Downgrade BDX BofA Securities Buy Neutral -- $190 May 1, 2025
Downgrade BDX Wells Fargo Overweight Equal Weight -- -- May 1, 2025
Upgrade BDX Citigroup Neutral Buy $255 $275 Oct. 1, 2024

News

Countdown to Becton Dickinson (BDX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
BDX
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral

Get a deeper insight into the potential performance of Becton Dickinson (BDX) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Read More
image for news Countdown to Becton Dickinson (BDX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
BD & Envetec Showcase Closed-Loop Recycling Solution for Lab Plastics
BDX
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral

BDX completes a pilot with Envetec showing polystyrene Petri dishes can be safely recycled into new medical-grade feedstock.

Read More
image for news BD & Envetec Showcase Closed-Loop Recycling Solution for Lab Plastics
Earnings Preview: Becton Dickinson (BDX) Q1 Earnings Expected to Decline
BDX
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Negative

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Earnings Preview: Becton Dickinson (BDX) Q1 Earnings Expected to Decline
10 Highest Rated Dividend Kings For Generations Of Income
ABBV, ABM, ABT, ADM, BDX, BKH, KMB, KO, MO, NWN, PG, PPG, SPGI, SWK, TGT, WMT
Published: January 29, 2026 by: Seeking Alpha
Sentiment: Positive

My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend safety/growth grades, and favorable Quant, SA, and Wall Street ratings. ABM Industries leads with a low 31% payout ratio, 2.5% yield, B- safety/growth, and an A- valuation grade despite a Hold Quant rating.

Read More
image for news 10 Highest Rated Dividend Kings For Generations Of Income
BDX Introduces BD Research Cloud 7.0 for Advanced Flow Cytometry
BDX
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive

BD launches BD Research Cloud 7.0 with AI-powered Horizon Panel Maker, boosting automation, data intelligence and productivity in flow cytometry.

Read More
image for news BDX Introduces BD Research Cloud 7.0 for Advanced Flow Cytometry
BDX vs. SAUHY: Which Stock Is the Better Value Option?
BDX, SAUHY
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Neutral

Investors interested in Medical - Dental Supplies stocks are likely familiar with Becton Dickinson (BDX) and Straumann Holding AG (SAUHY). But which of these two stocks offers value investors a better bang for their buck right now?

Read More
image for news BDX vs. SAUHY: Which Stock Is the Better Value Option?
Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
BDX
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Why Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
BD to Announce Financial Results for its First Quarter of Fiscal 2026
BDX
Published: January 27, 2026 by: PRNewsWire
Sentiment: Neutral

FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.

Read More
image for news BD to Announce Financial Results for its First Quarter of Fiscal 2026
BD Announces Record Date for the Spin-Off of its Biosciences & Diagnostic Solutions Business
BDX, WAT
Published: January 27, 2026 by: PRNewsWire
Sentiment: Neutral

Distribution date and closing date for spin-off and merger with Waters Corporation set for February 9, 2026 FRANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) ("BD" or the "Company") today announced that the Company's Board of Directors has set the close of business on February 5, 2026, as the record date for the previously announced spin-off of BD's Biosciences & Diagnostic Solutions business to BD's shareholders.

Read More
image for news BD Announces Record Date for the Spin-Off of its Biosciences & Diagnostic Solutions Business
Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business
BDX, WAT
Published: January 27, 2026 by: PRNewsWire
Sentiment: Neutral

Waters Corporation's Q4 2025 Financial Results Conference Call will now be held on Monday, February 9th, 2026 at 8:30am ET in conjunction with the expected close of the transaction MILFORD, Mass., Jan. 27, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) (the "Company" or "Waters") today announced that, at the Company's Special Meeting of Shareholders (the "Special Meeting") held today, Waters shareholders overwhelmingly voted to approve the issuance of shares of Waters common stock to shareholders of Becton, Dickinson and Company (NYSE: BDX) ("BD") in connection with the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters.

Read More
image for news Waters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions Business
Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term
BDX
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Read More
image for news Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term
BD and Ypsomed Expand Partnership to Target Growing Biologics Market
BDX
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive

BDX expands its Ypsomed partnership with a 5.5 mL Neopak XtraFlow syringe, targeting rising demand for large-volume subcutaneous self-injection.

Read More
image for news BD and Ypsomed Expand Partnership to Target Growing Biologics Market
BD Gets FDA 510(k) Approval for EnCor EnCompass Breast Biopsy System
BDX
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive

BDX wins FDA 510(k) clearance for the EnCor EnCompass breast biopsy system, set for an early 2026 launch to boost flexibility and patient care.

Read More
image for news BD Gets FDA 510(k) Approval for EnCor EnCompass Breast Biopsy System
Becton, Dickinson Wins FDA Clearance For Next-Gen Breast Biopsy Device, Launch Set For 2026
BDX, BDXA
Published: January 15, 2026 by: Benzinga
Sentiment: Positive

The U.S. Food and Drug Administration on Thursday granted 510(k) clearance for Becton, Dickinson and Company's (NYSE: BDX) new breast biopsy system.

Read More
image for news Becton, Dickinson Wins FDA Clearance For Next-Gen Breast Biopsy Device, Launch Set For 2026
Waters Corporation Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Waters Corporation - WAT
BDX, WAT
Published: January 07, 2026 by: PRNewsWire
Sentiment: Neutral

NEW YORK and NEW ORLEANS, Jan. 7, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Read More
image for news Waters Corporation Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Waters Corporation - WAT
Why The ‘Magnificent 7' Is Out In 2026 And These 3 Dividends Are ‘In'
BDX, MA, UNP
Published: January 07, 2026 by: Forbes
Sentiment: Neutral

Ignore the doom-and-gloom “predictions” about 2026. There are plenty of gains—and growing dividends—to be had for us this year.

Read More
image for news Why The ‘Magnificent 7' Is Out In 2026 And These 3 Dividends Are ‘In'
Best Dividend Aristocrats For January 2026
ABBV, ABT, ADM, ADP, AFL, ALB, AMCR, AOS, APD, ATO, BDX, BEN, BRO, CAH, CAT, CB, CHD, CHRW, CINF, CL, CLX, CTAS, CVX, DOV, ECL, BF-A, BF-B, ED, EMR, ERIE, ES, ESS, EXPD, FAST, FDS, FRT, GD, GPC, GWW, HRL, IBM, ITW, JNJ, KMB, KO, KVUE, LIN, LOW, MCD, MDT, MKC, NDSN, NEE, NOBL, NUE, O, PEP, PG, PNR, PPG, ROP, SHW, SJM, SPGI, SPY, SWK, SYY, TGT, TROW, WMT, WST, XOM
Published: December 31, 2025 by: Seeking Alpha
Sentiment: Positive

The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.

Read More
image for news Best Dividend Aristocrats For January 2026
BD and Penn Institute Ink Collaboration to Advance Immunotherapy
BDX
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive

BDX teams up with the Penn Institute for Immunology and Immune Health to launch a high-parameter immune profiling study.

Read More
image for news BD and Penn Institute Ink Collaboration to Advance Immunotherapy
Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term
BDX
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term
The Magnificent 7 Are So Yesterday. These Are AI's Next Big Winners
BDX, BME
Published: December 17, 2025 by: Forbes
Sentiment: Positive

Today I have a sweet dividend “double shot” for you: The first? A 2.8% payout set to grow thanks to AI—and take the stock price up with it.

Read More
image for news The Magnificent 7 Are So Yesterday. These Are AI's Next Big Winners
BD Expands BD MAX With IVDR-Approved VIASURE Tests in Europe
BDX
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive

BDX expands its BD MAX menu in Europe with IVDR-approved respiratory and STI assays, boosting system utility and reinforcing its diagnostics growth strategy.

Read More
image for news BD Expands BD MAX With IVDR-Approved VIASURE Tests in Europe
BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing
BDX
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive

BDX teams up with ChemoGLO to expand hazardous drug testing, aiming to boost safety in healthcare environments.

Read More
image for news BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
BDX
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read More
image for news Here's Why Becton Dickinson (BDX) is a Strong Value Stock
BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors
BDX
Published: November 17, 2025 by: PRNewsWire
Sentiment: Neutral

FRANKLIN LAKES, N.J. , Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025.

Read More
image for news BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors
BDX Unveils Portable PureWick System for On-the-Go Incontinence Care
BDX
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive

BD expands its PureWick line with a portable system built for discreet, mobile incontinence care, aiming to deepen its home-care reach.

Read More
image for news BDX Unveils Portable PureWick System for On-the-Go Incontinence Care
Becton, Dickinson and Company (BDX) Q4 2025 Earnings Call Transcript
BDX
Published: November 06, 2025 by: Seeking Alpha
Sentiment: Neutral

Becton, Dickinson and Company ( BDX ) Q4 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Adam Reiffe Thomas Polen - President, CEO & Chairman Christopher DelOrefice - Executive VP & CFO Conference Call Participants Travis Steed - BofA Securities, Research Division Patrick Wood - Morgan Stanley, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Hello, and welcome to BD's Fourth Quarter and Full Year Fiscal 2025 Earnings Call. At the request of …

Read More
image for news Becton, Dickinson and Company (BDX) Q4 2025 Earnings Call Transcript
3 Undervalued Dividend Kings to Buy on the Dip Right Now
BDX, HRL, TGT
Published: November 06, 2025 by: 24/7 Wall Street
Sentiment: Positive

Dividend Kings are stocks that've had their dividend payouts raised for 50 consecutive years or more, such as Target (NYSE:TGT ), Becton Dickinson (NYSE:BDX ), and Hormel Foods (NYSE:HRL ).

Read More
image for news 3 Undervalued Dividend Kings to Buy on the Dip Right Now
BD Stock Slips in Pre-Market Despite Q4 Earnings Beat, Margins Up
BDX
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Neutral

BDX tops fourth-quarter fiscal 2025 earnings estimates and posts strong margin gains, with growth across all business segments and geographies.

Read More
image for news BD Stock Slips in Pre-Market Despite Q4 Earnings Beat, Margins Up
Becton Dickinson (BDX) Reports Q4 Earnings: What Key Metrics Have to Say
BDX
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive

Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Read More
image for news Becton Dickinson (BDX) Reports Q4 Earnings: What Key Metrics Have to Say
3 Beaten-Down Dividend Aristocrats Ready to Rebound by 100%
BDX, BRO, FDS
Published: October 28, 2025 by: 24/7 Wall Street
Sentiment: Positive

Dividend Aristocrats are some of the best stocks to buy when they go on sale, as they're backed by companies on a solid footing.

Read More
image for news 3 Beaten-Down Dividend Aristocrats Ready to Rebound by 100%

About Becton, Dickinson and Company (BDX)

  • IPO Date 1973-02-21
  • Website https://www.bd.com
  • Industry Medical - Instruments & Supplies
  • CEO Thomas E. Polen Jr.
  • Employees 70000

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.